Search
News
Uni-Bio Science Group Announces 2025 Interim Results
EPS Surged to 1.27 HK Cents with a Three-year CAGRof43.1%Robust Revenue Growth Driven by Strong Demand for Bogutai® and Omnichannel Strategy(28 August 2025 – Hong Kong) A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2025 (the “Period”).Key Accomplishments in the First Half of 2025During the Period, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:During the Period, the Group delivered solid financial results, with revenue achieved an increase of 13.4% year-on-year (“YoY”) and net profit reaching a record HK$76.0 million, up 12.7% YoY, while EPS increased from HK$0.62 cents in the first half of 2023 to HK$1.27 cents in the first half of 2025, representing a three-year CAGR of 43.1%. The growth this year was driven by the Group’s omnichannel strategy and increasing demand for Bogutai®, along with in the Group’s existing marketed drugs. Meanwhile, the Group strengthened its financial position, with improvements across all key liquidity ratios and overall financial resilience. Since its official launch in March 2024, Bogutai® has steadily built market recognition and sustained growth momentum. Bogutai® has achieved solid progress in clinical uptake and patient enrollment, with over 8,000 new patients and 6,000 returning patients, and establishing a broad and in-depth market network across first- to fourth-tier markets. During the Period, revenue of Bogutai® increased substantially from approximately HK$18.8 million to approximately HK$65.6 million, representing a significant increase of 248.9%.In May 2025, the Group’s second ophthalmology product, 金因康® (Diquafosol Sodium Eye Drops), received marketing approval from the China National Medical Products Administration (“NMPA”), marking a significant milestone in expanding the Group’s ophthalmic portfolio. In July 2025, the marketing application of Isavuconazonium sulfoate capsules was officially accepted by the NMPA, marking a significant milestone for the Group in the field of antifungal treatment. Isavuconazonium sulfoate capsules is expected to be approved for launch in the second half of 2026.In June 2025, the Group officially launched the high-end series GeneQueens™ of 肌顏態® and the medical device brand 金因敷®, marking a key milestone in its strategic expansion into the integrated "Drug, Medical Device, and Aesthetics" field.During the Period, the Group is refocusing its R&D strategy on regenerative medicine. In particular, the Group is in discussions with leading regenerative medicine research institutions in China to establish industry–academic partnerships in this field, aiming to co-develop innovative therapies leveraging growth factors and regenerative medicine technologies, combining complementary strengths to accelerate research and further strengthen the Group’s leadership in biopharmaceutical innovation.Interim ResultsFor the Period, the Group recorded revenue of approximately HK$310.2 million, representing an increase of 13.4% YoY. Revenue of Bogutai® increased substantially from approximately HK$18.8 million to approximately HK$65.6 million, representing a significant increase of 248.9%. Revenue generated from GeneTime® was approximately HK$107.8 million, representing an increase of 18.1% YoY. GeneSoft® recorded a mild decrease in revenue to approximately HK$18.5 million, representing a decrease of 2.1% YoY. Currently, the Group is preparing for GeneSoft® entry into medical insurance coverage, aiming for inclusion by the end of 2025, and providing a strong catalyst for future growth. Pinup® recorded a decrease of 22.7% in revenue to approximately HK$108.9 million for the Period. The Group was re-selected for the centralized procurement in 2024, with a validity period of two years. However, in response to certain local policy changes, the Group adopted a more selective approach to hospital supply. Hospitals in many provinces began procuring Boshutai® in 2025. Revenue from Boshutai® was approximately HK$6.1 million, representing a significant increase of 84.8%.Gross profit was approximately HK$254.1 million, representing an increase of 10.2% YoY, whereas gross profit margin was 81.9% (first half of 2024:84.3%). The decrease in gross profit margin was primarily due to the recent addition of Bogutai®, which is still in the early stages of commercialization and had a relatively low output volume, resulting in higher product costs. Profit for the Period surged from approximately HK$67.4 million in the first half of 2024 to approximately HK$76.0 million, representing an increase of 12.7%. This result reflects the effectiveness of the Group’s strategic focus on operational efficiency, disciplined cost control, and targeted commercial execution, reinforcing its trajectory toward sustained profit growth and long-term value creation. The earnings per share reached approximately HK$1.27 cents, reflecting a growth of 16.5% YoY.ProspectsChina’s medical device industry is expected to grow at an 8.9% CAGR from 2023 to 2030, fueled by rising chronic diseases and innovation investment. Government policies like “Made in China 2025” and the 2025 “Measures to Support High-Quality Development of Innovative Drugs” promote drug innovation, expanded insurance, faster approvals, and prioritize key therapies, including pediatric, chronic, and infectious diseases. National procurement now favors innovation over price, supporting sustainable healthcare growth. Leveraging advanced synthetic biology, the Group is well-positioned to seize these opportunities and advance regenerative therapies in orthopedics, ophthalmology, dermatology, and medical aesthetics.Looking forward, Mr. Kingsley Leung, Chairman of Uni-Bio Science said, “We are committed to pursuing a diversification strategy to ensure sustainability by driving product innovation and expanding marketing channels and geographical presence. During the Period, we achieved notable breakthroughs in our product portfolio. We received marketing approval of our new ophthalmology product, 金因康®, and antifungal product, isavuconazonium sulfoate capsules. Our medical aesthetic products also experienced a major launch with the introduction of the high-end GeneQueens™ series, along with a new medical device brand, 金因敷®.We have implemented omnichannel strategies to broaden our customer base beyond traditional hospital networks. Our direct sales team works closely with multiple-tier hospitals, while our own flagship stores are established on all major Chinese online sales platforms. We will continue to grow our online presence and expand our distributor network to support offline marketing. Internationally, we are focusing on markets such as the U.S., Middle East, and Southeast Asia. Our FDA application for Bogutai® is progressing, with approval expected as early as 2027, targeting it as our first overseas commercial product.During the Period, we further re-focused our R&D strategy in regenerative medicine. To enhance our core strengths and enter advanced therapies, we established two cutting-edge R&D platforms: the ECO-KSFA® Mini-protein Superfactory, which enables large-scale production of complex-structured polypeptides while significantly reducing costs; and the Biological Hydrogel Technology Platform, designed to incorporate active molecules such as growth factors for enhanced tissue engineering repair. These platforms form the basis of our R&D and will boost our product innovation.”About Uni-Bio Science Group LimitedUni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.For further information, please contact: ir@uni-bioscience.com 28/08/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Aug 28, 2025
BYD European Sales Soar 225% in July, Overtaking Tesla in Market Share
TradingKey - Chinese new energy vehicle leader BYD achieved explosive sales growth in the European market in July, surpassing Tesla in market share and becoming a focal point for the global automotive industry.TradingKey
Aug 28, 2025
Snowflake's "Perfect Scorecard": AI Cloud Engine Drives Growth; Shares Jump After Hours
TradingKey - Cloud data warehouse giant Snowflake (SNOW.US) posted impressive second-quarter earnings on August 27, with core financial metrics showing strong performance and an upwardly revised full-year revenue guidance — both exceeding market expectations. Robust growth in its AI data cloud...
TradingKey
Aug 28, 2025
Meituan's Q2 Profit Slump by 87% Spurs Divergent Views: Market Share Erosion or Long-term Strength?
TradingKey - On August 28th, Meituan (3690.HK) tumbled more than 10% at the opening of the Hong Kong market, closing down 13.07% at HK$101.1, hitting a new low since last September. The primary reason was the Q2 financial report falling significantly short of expectations, with net profit plunging 8
TradingKey
Aug 28, 2025
Japanese Trading Houses Surge — Buffett’s Stake Hike Acts as Key Catalyst
TradingKey - Berkshire Hathaway, led by Buffett, has once again increased its exposure to Japan, sparking a broad rally in the country’s trading house sector. On Thursday local time, Mitsubishi Corporation announced that a subsidiary of Berkshire had raised its stake from 9.74% in March to 10%TradingKey
Aug 28, 2025
Li Auto Shares Fell On Missing Q2 Estimates
Li Auto (NASDAQ:LI): Q2 Non-GAAP EPADS of $0.19 misses by $0.05. Revenue of $4.2B (-4.5% Y/Y) misses by $250M.Li Auto shares fell 5% in premarket.Q3 outlook: Total revenues to be between RMB24.8 billion (US$3.5 billion) and RMB26.2 billion (US$3.7 billion), representing a year-over-year decrease of ...Tiger News
Aug 28, 2025
HK Movers | Horizon Robotics Jumps 13% on Strong First Half Performance
Shares of Horizon Robotics surged 12.9% in Hong Kong in the afternoon.The boost comes as Horizon Robotics released its interim results. First half revenue reached RMB 1.567 billion, an increase of 67.6% year-on-year; gross profit amounted to RMB 1.024 billion, with a comprehensive gross margin of 65...Tiger News
Aug 28, 2025
Crypto Daily | Spot Ether ETFs See $1.83 Billion Inflows in Five Days; Stablecoin Groups Circle, Paxos Test New Tech to Verify Crypto Payments
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsStablecoin Groups Circle, Paxos Test New Tech to Verify Crypto PaymentsStablecoin heavyweights Circle Internet Group Inc. and Paxos Trust Co. have piloted a new way...Tiger News
Aug 28, 2025
NVIDIA Posts Strong Revenue and Profit Beat — So Why Did Shares Drop Over 5% After Hours? What Is the Market Worried About?
TradingKey - The much-anticipated Q2 2026 earnings report from NVIDIA (NVDA.US) is in:Revenue of $46.74 billion. Net income of $26.42 billion. Both figures surged over 55% year-over-year and exceeded analyst expectations. Yet, the stock plunged more than 5% in after-hours trading
TradingKey
Aug 28, 2025
Alibaba in Talks to Refinance $6.5 Billion Loan Amid Cloud and AI Push
Alibaba Group Holding Ltd. is negotiating with banks to refinance a $6.5 billion loan due next year, according to people familiar with the matter.The company is offering existing lenders a pricing of below 80 basis points over the Secured Overnight Financing Rate for a five-year revolving credit fac...Tiger News
Aug 28, 2025
Gold Prices Soar — So Why Is the World’s Largest Gold Miner Cutting Jobs?
TradingKey - Despite gold prices hitting record highs, Newmont Corporation (NEM.US), the world’s largest gold miner, is under severe cost pressure and is now planning large-scale layoffs to reduce expenses.
TradingKey
Aug 28, 2025
HK Movers | Meituan, Alibaba, and JD.com Sink as Competition Intensifies
China’s key players in the food delivery market fell in Hong Kong. Meituan dropped more than 11%, while Alibaba fell 4% and JD.com lost 3%.China's leading food delivery group Meituan posted an 89% drop in second-quarter adjusted net profit on Wednesday, hit by rising competition in the so-called ins...Tiger News
Aug 28, 2025
Zhihu Shares Surge After It Posts Better-than-Expected Earnings
Zhihu's stock price surged 7% in Hong Kong and 6% in U.S. overnight trading, drawing market attention. This upward trend is primarily due to the company's release of its second-quarter 2025 earnings report, which exceeded market expectations.The financial report shows that Zhihu achieved revenue of ...Tiger News
Aug 28, 2025
24H | Trip.com Jumps over 8%; Tuya Gains Nearly 7%; SOXL, Super Micro Drop over 2%; Alibaba Falls 2%
Alibaba stock fell 2% in overnight trading. China's Alibaba is likely to highlight its artificial intelligence strategy with its quarterly results on Friday.The companies have invested billions of dollars into AI over the past three years following the global success of ChatGPT, hailing it as a key ...Tiger News
Aug 28, 2025
24H｜Nvidia Drops 3%; CrowdStrike Sinks 4%; Snowflake Jumps 13%; Pure Storage Surges 16%
Nvidia dropped 3.1% in overnight trading. The world’s most valuable company gave a tepid revenue forecast for the current period, signaling that growth is decelerating after a staggering two-year boom in artificial intelligence spending.Tiger News
Aug 28, 2025
Post-Bell | S&P 500 Notches Record Close; MongoDB Soars 38%; Kohl's Surges 24%; Canada Goose Jumps 16%
The S&P 500 notched a record high close on Wednesday ahead of quarterly results from Nvidia, Wall Street's most closely watched event this week, which will test the rally that has pushed valuations of AI-related companies to levels that some investors view as too high.Market SnapshotThe S&P 500 clim...Tiger News
Aug 27, 2025
Featured Tools
Top News
Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?
【US Pre-Market】Nasdaq Leads Losses in Three Major Stock Index Futures, IONQ Surges Over 11%, RGTI Rises Over 5% as Market Focuses on US-China Summit
Today’s Market Recap: 10-Year Treasury Yield Hits Highest Level Since 2007, Major U.S. Indexes Fall, SpaceX Drops Over 4%
Meta Connect 2026 Preview: Phoenix Headset and AI Glasses Take Center Stage, Can Meta Reshape the XR Ecosystem?
Qualcomm Extends Long-Term Patent Agreement With Apple, Securing QTL Revenue in Era of In-House iPhone Modems
Market Movers
Aurora Innovation Inc Stock (AUR) Moved Down by 8.78% on Sep 24: What Investors Need To Know
17 minutes ago
AUR
--
SanDisk Corporation Stock (SNDK) Moved Down by 3.62% on Sep 24: What Investors Need To Know
17 minutes ago
SNDK
--
Gen Digital Inc Stock (GEN) Moved Down by 8.39% on Sep 24: Drivers Behind the Movement
17 minutes ago
GEN
--